Background: The aim of this study was to investigate the dose-limiting toxicities (DLTs) and determine the recommended doses in the Phase I part of the study, and to evaluate the efficacy and toxicity in the Phase II part, of continuous hepatic intra-arterial infusion therapy with 5-fluorouracil, mitoxantrone and cisplatin (FMP therapy) in patients with advanced hepatocellular carcinoma (HCC). Methods: Forty-five patients with advanced HCC were enrolled. The therapy consisted of continuous intra-arterial infusion of 5-fluorouracil from Day 1 through Day 5, and intra-arterial administration of mitoxantrone and cisplatin on Day 1 [5-fluorouracil/mitoxantrone/cisplatin (mg/m
Introduction
Chemotherapy for advanced hepatocellular carcinoma (HCC) is employed to treat patients who are judged as being unsuitable candidates for surgical resection, local ablative therapy or transarterial chemoembolization (TACE) , that is, patients with extrahepatic metastasis, vascular invasion or refractory to TACE (1) (2) (3) (4) (5) (6) . Chemotherapy for advanced HCC can be classified into systemic chemotherapy and hepatic arterial infusion chemotherapy (HAIC). In Japan, HAIC is mainly employed for patients with localized advanced HCC, e.g., those with evidence of vascular invasion (1) (2) (3) (4) , while systemic chemotherapy (using sorafenib, which is acknowledged as the standard treatment for HCC (5, 6) ), is mainly employed for advanced HCC patients with extrahepatic metastasis. As HAIC is associated with increased local concentrations of the administered anticancer agents in the tumor and a reduced systemic distribution of the drugs, a stronger antitumor effect and lower incidence of systemic adverse reactions may be expected as compared with systemic chemotherapy. In fact, high response rates, favorable long-term outcomes, and acceptable toxicities have been reported by a number of investigators (7) (8) (9) (10) (11) (12) (13) (14) . However, no consensus has been reached as to its place as a standard treatment for advanced HCC, because no randomized controlled trials have yet demonstrated any survival advantage of HAIC. In regard to the chemotherapeutic regimen(s) used for HAIC, the optimal treatment regimen for advanced HCC still remains under debate (1) (2) (3) (4) (7) (8) (9) (10) (11) (12) (13) (14) .
In a Phase II trial conducted by our group, systemic administration of the 5-fluorouracil, mitoxantrone and cisplatin (FMP) regimen, which consists of three kinds of cytotoxic agents (5-fluorouracil, mitoxantrone and cisplatin), showed a synergistic effect of cisplatin and 5-fluorouracil or mitoxantrone against various cancers (15, 16) , and the FMP regimen was found to exert promising antitumor activity (response rate: 27%; median progression-free survival time: 4.0 months; median survival time: 11.6 months) with tolerable toxicity in patients with metastatic HCC (17) . Although the randomized controlled trial of this regimen has not been conducted to elucidate the survival benefit, this regimen was found to exert the most favorable tumor shrinkage effect among the cytotoxic regimens used in systemic chemotherapy for advanced HCC. We considered that if this regimen could be adapted for HAIC, greater efficacy for intrahepatic tumors could be achieved as compared with that obtained by systemic therapy using the same drugs. Therefore, we performed this trial of HAIC using the FMP regimen in patients with advanced HCC. The aim of this study was to investigate the dose-limiting toxicities (DLTs) and determine the recommended doses in the Phase I part, and to evaluate the efficacy and toxicity in the Phase II part, of intra-arterial FMP therapy for advanced HCC.
Patients and methods

Patient eligibility
Patients with unresectable HCC that was not amenable to curative treatments were eligible for enrollment in this study. The patient inclusion criteria were as follows: advanced HCC confirmed by histological examination or by the presence of typical computedtomographic (CT)/magnetic resonance (MR) or angiographic findings with elevated serum alpha-fetoprotein (AFP) levels; lack of indications for surgical resection, local ablative therapy or TACE; measurable disease; presence of intrahepatic tumors affecting the prognosis, irrespective of the presence of extrahepatic tumors; age 20 years or over; Eastern Cooperative Oncology Group performance status 0-1; hepatic arterial catheter and port (reservoir system) placed and adequate drug distribution confirmed by CT or MR during arteriography via the indwelling catheter; adequate organ functions (white blood cell count ≥3 000/mm 3 , hemoglobin ≥9.0 g/dL, platelet count ≥70 000/mm 3 , serum total bilirubin ≤2.0 mg/dL, serum albumin ≥3.0 g/dL, serum levels of aspartate aminotransferase [AST] and alanine aminotransferase [ALT] ≤200 U/L, serum creatinine ≤1.1 mg/dL, creatinine clearance ≥60 ml/min); Child-Pugh class A or B; HAIC technically feasible; interval of 4 weeks or longer from the last treatment to patient enrollment, with no influence of previous treatments; life expectancy of at least 8 weeks; availability of written informed consent.
The exclusion criteria were as follows: prior chemotherapy with 5-fluorouracil, mitoxantrone or cisplatin for HCC; refractory pleural effusion or ascites; allergic to iodine contrast medium precluding angiography; presence of severe and active co-morbidity(ies), such as severe heart disease; acute myocardial infarction within 6 months prior to enrollment; active infection(s) excluding hepatitis B or C; active concomitant malignancy; severe mental disorder; severe drug allergy; pregnant or lactating women; women of childbearing age unless using effective contraception; poor general condition precluding participation in this study as judged by the primary physician.
The pretreatment evaluation included a complete history and physical examination; baseline laboratory evaluation consisted of the following: complete and differential blood counts, serum biochemistry, serum viral marker profile, including hepatitis B surface antigen and hepatitis C antibody, urinalysis, and serum levels of tumor markers, including AFP and protein induced by vitamin K absence or antagonist-II (PIVKA II). Dynamic CT or MR of the abdomen and X-ray or CT of the chest were performed in each patient for pretreatment staging to assess the local extent of the tumor and to evaluate the presence of distant metastasis. Finally, an indwelling reservoir system was placed in each of the patients prior to his/her enrollment in this trial. The method used for the reservoir system was not regulated in this trial.
Treatments
This was an open-label, multi-institutional, single-arm Phase I/II trial that was conducted with the approval of the review board of each of the participating institutions and in accordance with the principles laid down in the Declaration of Helsinki. This trial is registered with UMIN-CTR (http://www.umin.ac.jp/ctr/index-j.htm); identification number (UMIN000000487).
Intra-arterial FMP therapy was administered as follows to the enrolled patients: 5-fluorouracil was administered by continuous intraarterial infusion from Day 1 through Day 5, mitoxantrone was administered by intra-arterial infusion over 30 min on Day 1, and cisplatin was administered by intra-arterial infusion over 30 min on Day 1 with standard hydration. The treatment was repeated every 4 weeks up to a maximum of six cycles, or until appearance of evidence of radiological or symptomatic tumor progression, appearance of unacceptable toxicity(ies), or emergence of technical difficulties in repeating the HAIC, such as hepatic artery occlusion, catheter thrombosis, etc. If the protocol therapies were discontinued, the patient was allowed to receive other anticancer treatment(s) at the discretion of the treating physician.
Phase I part
The doses of each of the chemotherapeutic agents are shown in Table 1 , and initial dose level was the dose level used at Level 1.
The maximum doses (Level 3) of 5-fluorouracil and mitoxantrone were similar to those used in systemic chemotherapy, while the maximum dose (Level 3) of cisplatin was lower than that used in systemic chemotherapy. Since the recommended dose of intra-arterial cisplatin monotherapy determined from Japanese trials (7) is 65 mg/m 2 , the maximum cisplatin dose (Level 3) was set at 60 mg/m 2 .
The patient cohort consisted of a minimum of three patients at each dose level. If no DLT was observed in the initial three patients, the dose was escalated in successive cohorts. If DLT was observed in one or two of the initial three patients, three additional patients were evaluated at that dose level; if only one or two of these six patients experienced DLTs, the dose escalation was continued. However, if three or more patients experienced DLT at a given dose level, then the previous dose level was considered as the maximum tolerated dose. The following toxicities manifesting during first course of intra-arterial FMP therapy were defined as DLTs: Grade 3 leukocytopenia and/or neutropenia with high fever (≥38°C) lasting for 5 days or more, Grade 3 leukocytopenia and/or neutropenia with infection, Grade 4 leukocytopenia and/or neutropenia lasting for 5 days or more, Grade 4 leukocytopenia and/or neutropenia necessitating administration of granulocyte colony-stimulating factor, platelet count <25 000/mm 3 , Grade 3 thrombocytopenia requiring platelet transfusion, serum AST/ALT ≥10 times the UNL, Grade 3 or 4 non-hematological toxicities excluding anorexia, nausea, vomiting, fatigue and hyperglycemia, or difficulty in starting the subsequent course of treatment within 8 weeks of the initiation of the previous course of intra-arterial FMP therapy. In the patients who developed DLTs, the doses of the drugs were adjusted in subsequent courses as follows: to 100 mg/m 2 for 5-fluorouracil, 2 mg/m 2 for mitoxantrone and 10 mg/m 2 for cisplatin.
The initiation criteria for administering subsequent courses of intraarterial FMP therapy were as follows: proper distribution of contrast medium to the entire liver from the indwelling reservoir system as confirmed by CT or MR during arteriography via the indwelling catheter; white blood cell count ≥2 500/mm 3 , platelet count ≥50 000 /mm 3 , serum total bilirubin ≤2.0 mg/dL, serum AST or ALT ≤200 U/L, and serum creatinine ≤1.5 mg/dL. If the aforementioned criteria to start the next course of therapy were not met, the intra-arterial FMP therapy was postponed until the criteria were fulfilled. An anti-emetic agent, usually a 5-HT3 receptor antagonist, and dexamethasone were administered prophylactically. Granulocyte colony-stimulating factor was given to patients with Grade 4/Grade 3 neutropenia and/or leukocytopenia with high fever (≥38°C).
Phase II part
The patients enrolled in the Phase II part of this trial received intraarterial FMP therapy according to the recommended doses for each of the agents determined from the Phase I part of the trial. The methods of administration of the drugs were the same as those in the Phase I part. The patients in Phase II included those patients who received intra-arterial FMP therapy at the recommended doses in Phase I.
Response and toxicity assessment
Assessment of adverse events was based on the National Cancer Institute Common Toxicity Criteria, version 3.0. During the intraarterial FMP therapy, physical examination and basic laboratory tests, including a complete blood count/differential blood counts and serum chemistry tests were performed at least once every 2 weeks. Evaluation of the tumor response by dynamic CT or MR was performed every 4 weeks using the Response Evaluation Criteria in Solid Tumors (RECIST) (18) . Serum levels of AFP and PIVKA-II were measured every 4 weeks. Overall survival was measured from the date of enrollment to the date of death or date of the last follow-up. Progression-free survival was defined as the time from the date of enrollment to the first documentation of disease progression or death.
Statistical analysis
The objective of the Phase I part of the trial was to determine the recommended doses for intra-arterial FMP therapy based on the frequency of DLT, and the objective of the Phase II part was to evaluate the antitumor efficacy and safety of the treatment. The number of patients to be enrolled in the Phase II part was planned using a two-step design (19) based on the assumption that the response rate would be 40%, the response rate judged as no activity would be 20%, with an α error of 10% and β error of 10%, with reference to the response of systemic administration of the FMP regimen (27%) (17) and of intra-arterial cisplatin monotherapy (33%) (7) . An interim analysis was planned after 20 patients had been enrolled. If three or fewer of the first 20 patients showed partial response or complete response, the study was to be ended. If a response was detected in four or more of the first 20 patients enrolled, an additional 15 patients were to be enrolled in a second stage of accrual to estimate the actual response rate more precisely. If a response was detected in 12 or more of the final 35 patients, the intra-arterial FMP therapy would be judged as being favorable. This population for analysis included all patients who had received at least one course of the study medication. The survival time and the progression-free survival time were calculated by the Kaplan-Meier method. All the data were frozen on 30 September 2009.
Results
Patient characteristics
A total of 45 patients were enrolled in this trial between October 2005 and September 2008. Fifteen patients (Level 1, six patients; Level 2, three patients; Level 3, six patients) were enrolled in the Phase I part. An additional 30 patients were enrolled in the Phase II The treatment was repeated every 4 weeks up to a maximum of six cycles. DLT, dose-limiting toxicity.
part, and a total of 36 patients, including the six patients from Level 3 (recommended dose level), were included as the subjects for the Phase II part of the trial. The patient characteristics of the 15 patients in the Phase I part and 36 patients in the Phase II part of the trial are shown in Table 2 . All patients showed a good performance status (0-1). Of the patients, 32 (88%) were classified into Child-Pugh class A and 13 (12%) into Child-Pugh class B.
Approximately two-thirds of the enrolled patients had vascular invasion and about one-third had extrahepatic metastases. The main site of extrahepatic metastasis was the lung (11 patients), followed by the lymph nodes and pleura (two patients each).
Phase I part
A total of 15 patients, including six patients at Level 1, three patients at Level 2 and six patients at Level 3, were enrolled in the Phase I part of the trial between October 2005 and October 2006. One patient from Level 1 developed the DLT of pulmonary embolism. This DLT developed on Day 5 of the first course of treatment in a patient with tumor thrombosis in the inferior vena cava, and its relationship to the trial treatment was rated as 'probable'. Therefore, an additional three patients were enrolled in Level 1, and no further DLTs developed at Level 1. Furthermore, no DLTs were encountered at Level 2 or 3 either. The main Grade 3/4 adverse events were 3-4 neutropenia (53%), leukocytopenia (33%), thrombocytopenia (20%), increased AST (13%), increased ALT (13%), and increased total bilirubin (7%). The other important adverse event was occlusion of the hepatic artery which was detected during the arterial infusion of 5-fluorouracil; this adverse event developed in two patients at Level 1. Therefore, a study committee for safety and efficacy monitoring was constituted to discuss the significance of this event encountered in two patients. The committee recommended combined administration of hydrocortisone 50 mg/day with 5-fluorouracil as a tentative prophylactic measure against hepatic arterial occlusion (20,21). There were no cases of occlusion of the hepatic artery at Level 2 or Level 3. On the basis of the results of the Phase I part, this regimen was judged to be tolerable, and the dose levels at Level 3 were determined as the recommended dose levels (5-fluorouracil, 500 mg/m 2 /day; mitoxantrone, 6 mg/m 2 ; cisplatin, 60 mg/m 2 )
Phase II part
The efficacy and safety were evaluated in all 36 patients enrolled at Level 3 of the Phase II part. The median number of treatment courses was 3 (range, 1-6). Only three of all the patients required any dose modifications. A total of 34 patients had discontinued the treatment by the time of the final analysis, and 28 of these (78%) received subsequent therapies, including TACE (eight patients), systemic FMP therapy (seven patients), radiation (six patients), other HAIC (three patients), surgical resection (three patients), or other systemic therapy (one patient). The numbers of patients who showed complete response, partial response, stable disease, and progressive disease according to the RECIST criteria were 0, 9, 22, and 5, respectively. The response rate (95% confidence interval (CI)) was 25% (12-42%), and the primary endpoint of the Phase II study was not met. The disease control rate (95% CI) was 86% (71-95%). By the time of the final analysis, 30 patients had died. The median survival time and 1-year and 2-year survival rates were 11.3 months, 46.9% and 13.1%, respectively (Figure 1 ). At the data cutoff point, disease progression was observed in 26 patients, and the median progression-free survival time was 7.3 months (Figure 1 ). Three patients showing partial response were treated by surgical resection for the residual HCC lesions. The resections were successful in all three patients, and all three achieved complete clinical remission after the surgery. During the treatments, the serum AFP level decreased by more than 50% in 13 (59%) of the 22 patients with pretreatment levels of ≥100 U/ml, and the serum PIVKA II level decreased by more than 50% in 25 (74%) of the 34 patients with pretreatment levels of ≥100 mAU/ml. The adverse events encountered during the entire treatment period until the final analysis are shown in Table 3 . The main adverse events were myelosuppression (leukocytopenia, neutropenia, thrombocytopenia), liver dysfunction (increased total bilirubin, AST, and ALT), anorexia and nausea. However, all of these adverse events were transient and resolved completely within 1 month. Another important adverse event was catheter troubles in nine patients (25%). Furthermore, occlusion of the hepatic artery, similar to that observed in the two patients at Level 1, developed in eight patients (22%) despite prophylactic hydrocortisone at 50 mg/day having been administered to all eight patients, necessitating discontinuation of the intra-arterial FMP infusion therapy in six of the eight patients (75%) ( Table 4 ). There were no treatment-related deaths in this series.
Discussion
A previous Phase II trial reported favorable efficacy of systemic FMP therapy for metastatic HCC (17) and its tumor shrinkage effect could be expected to higher than the other cytotoxic chemotherapeutic regimens for advanced HCC, although no Phase III trial has been conducted so far. Especially, the response rate was higher than that to sorafenib treatment or the other systemic chemotherapies for advanced HCC (1-6) . Therefore, it appears that intra-arterial FMP therapy may have a more favorable tumor shrinkage effect as compared with systemic FMP therapy, because a stronger antitumor effect than that obtained with systemic chemotherapy might be expected because of the administration of the drugs directly into the hepatic artery. To verify our hypothesis, we conducted a Phase I/II trial of intra-arterial FMP therapy in patients with advanced HCC. However, contrary to our expectation, the primary endpoint of the tumor response was not met, and the tumor response in this study was not superior to that noted to systemic FMP therapy (Table 5 ). There could be some reasons, discussed below, as to why this study did not yield the expected results. The first reason is that the patient characteristics differed between this study and the study of systemic FMP therapy (Table 5 ). The proportions of patients with vascular invasion and bilateral distribution of the intrahepatic HCC in the Phase II part of our trial were much higher than those in the systemic FMP trial. Thus, the patients enrolled in the Phase II part of our trial might have had more advanced intrahepatic lesions. Second, catheter troubles were encountered in about a quarter of the entire population; hepatic artery occlusion as the cause of the catheter troubles was observed in a high proportion of cases (22%). These catheter troubles necessitated discontinuation of the intraarterial FMP therapy, and these patients could eventually not receive sufficient doses of the FMP therapy. Finally, FMP therapy itself might not be more effective, contrary to expectation, when administered intra-arterially, because the progression-free and overall survival rates after intra-arterial FMP therapy were quite similar to those after systemic FMP therapy. 1  0  2  0  0  2  0  0  12  9  0  0  0  Leukocytopenia  2  3  0  2  1  0  4  1  0  5  14  11  2  36  Neutropenia  2  3  0  0  3  0  3  2  0  7  10  11  3  39  Thrombocytopenia  2  1  1  2  1  0  3  0  0  8  11  7  0  19  Nausea  4 The adverse events of intra-arterial FMP therapy seemed to be milder than those of systemic FMP therapy (Table 4 ). In general, systemic distribution of anticancer agents is reduced by intra-arterial administration, because the drugs undergo first-pass metabolism in the liver (1, 2, 4) . In this study, the incidences of almost all adverse events of FMP, excluding abdominal pain, such as myelosuppression, gastrointestinal toxicities and liver dysfunction, were reduced by intra-arterial administration. In terms of these toxicities, intraarterial FMP therapy was more feasible than systemic FMP therapy, although there were only slight differences in the doses of the anticancer agents between the two therapeutic modalities (Table 5) .
A high frequency of hepatic artery occlusion (22%) was noted in this trial (Table 4) , although according to a previous review, this complication was reportedly observed in only 6% of 4580 patients receiving HAIC (23) . Thus, the frequency in this trial seemed to be higher than that in other studies. The interventional radiologists (YI, YS, TK, and YA) in each institution participating in this trial were technically skilled and well-experienced in the technique of indwelling catheter placement into the hepatic arteries (22) , as they were all board-certified specialists of the Japanese Society of Interventional Radiology. In addition, intra-arterial hydrocortisone was prophylactically administered to all of the patients in the Phase II part of the trial (20, 21) . While the reason for the higher incidence of this complication remains unknown, this triplet regimen using 5-fluorouracil, mitoxantrone and cisplatin could be harmful to the hepatic arteries in HCC patients.
HAIC is often employed for patients with localized advanced HCC, especially in Japan High response rates and favorable longterm outcomes of HAIC have been reported. However, no randomized controlled trials have demonstrated any survival advantage of HAIC, and no consensus has been reached as to the standard treatment for advanced HCC (2, 3) . On the other hand, as systemic chemotherapy for advanced HCC, sorafenib is currently acknowledged as the standard of care (4, 5) . Although sorafenib has only a modest tumor shrinkage effect, it has been demonstrated to offer survival benefit in advanced HCC patients. In addition, sorafenib, being an orally administered drug, is easier to administer than HAIC. However, the attractive part of HAIC is that it allows for a stronger antitumor effect of the drugs and sometimes converts patients into suitable candidate for curative surgical resection. In this trial, three patients in whom partial response was obtained in response to intra-arterial FMP therapy subsequently underwent curative surgical resection and showed cancer-free survival. Therefore, HAIC is still often performed in Japan, and some clinical trials of HAIC are under way. Recently, a randomized controlled trial of sorafenib plus HAIC with cisplatin as compared with sorafenib alone demonstrated a favorable overall survival in the former arm as compared with the latter arm in patients with advanced HCC (24) . However, a Phase III trial of sorafenib plus intra-arterial cisplatin and 5-fluorouracil vs. sorafenib alone (25) failed to demonstrate any survival benefit, although a tendency towards a favorable response was seen in a subgroup of patients with tumor thrombosis in the main portal vein. Thus, the survival benefit of HAIC remains controversial. Currently, HAIC is at a crucial crossroads in terms of whether it will be acknowledged as one of the standard treatments for HCC.
In conclusion, intra-arterial FMP therapy was feasible in all patients except those that developed occlusion of the hepatic artery, however, no favorable tumor response and survival could be demonstrated in patients with advanced HCC. Therefore, we do not recommend further evaluation of this intra-arterial regimen. In the future, however, it is necessary to elucidate, by well-designed randomized controlled Phase III studies, whether HAIC using other regimens might yield some survival benefit in patients with advanced HCC. 
